Episode Details
Back to Episodes
FDA Approves New Breast Cancer Drug | Ottawa News
Description
FDA just approved Revtorpyk, Celcuity’s first drug, for advanced breast cancer that’s resistant to standard treatments — and it’s a game-changer. When paired with Pfizer’s Ibrance and fulvestrant, the combo slashes disease progression or death risk by 76% compared to fulvestrant alone. Patients with specific tumor profiles — low HER2, no PIK3CA mutation — saw a median of 9.3 months without progression, up from just 2.0 months. This targeted therapy offers new hope where previous treatments failed.
Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/c77e61097bc310a4